Mindray Displays New Generation Benchtop Cellular Analysis Line
|
By LabMedica International staff writers Posted on 31 Jan 2019 |

Image: The CAL 6000 benchtop cellular analysis line (Photo courtesy of Mindray).
Mindray (Shenzhen, China) exhibited its new generation benchtop cellular analysis line at MedLab Middle East, an international platform for laboratory management and medicine that brought together more than 700 exhibitors and over 35,000 professionals. MedLab Middle East 2019 took place at the Dubai International Convention and Exhibition Centre, Dubai, UAE from the 4th to the 7th of February.
Among Mindray’s latest innovations displayed at MedLab Middle East 2019 was CAL 6000, a benchtop cellular analysis line that connects two units of BC-6000 or BC-6200 auto hematology analyzers and one unit of SC-120 auto slide maker & stainer. The compact workstation helps save more laboratory space while delivering a fast throughput of up to 220 samples and 120 slides per hour. It provides automated body fluids test results, and is equipped with labXpert data management software for automatic sample validation and analysis.
At MedLab Middle East 2019, Mindray also exhibited the CL-900i chemiluminescence immunoassay analyzer, which has an industry-leading small benchtop footprint, a throughput of up to 180 tests per hour and 15 reagent positions. The CL-900i is a state-of-the-art system that is compact, fast and accurate, offering automation and reliable performance to ensure quality testing results with minimal hands-on time.
Among Mindray’s latest innovations displayed at MedLab Middle East 2019 was CAL 6000, a benchtop cellular analysis line that connects two units of BC-6000 or BC-6200 auto hematology analyzers and one unit of SC-120 auto slide maker & stainer. The compact workstation helps save more laboratory space while delivering a fast throughput of up to 220 samples and 120 slides per hour. It provides automated body fluids test results, and is equipped with labXpert data management software for automatic sample validation and analysis.
At MedLab Middle East 2019, Mindray also exhibited the CL-900i chemiluminescence immunoassay analyzer, which has an industry-leading small benchtop footprint, a throughput of up to 180 tests per hour and 15 reagent positions. The CL-900i is a state-of-the-art system that is compact, fast and accurate, offering automation and reliable performance to ensure quality testing results with minimal hands-on time.
Latest MEDLAB 2019 News
- ERBA Group Launches New Hematology Analyzers at MEDLAB 2019
- Telstar Promotes Latest Generation of Freeze Dryers in Dubai
- Siemens Healthineers Showcases In-Vitro Diagnostics Products at MedLab 2019
- Randox Promotes Evidence MultiSTAT Automated Benchtop Immunoassay Analyzer
- HORIBA Medical Shows Latest Yumizen G Range at Lab Trade Show
- Greiner Bio-One Displays Range of Safety Products at MedLab
- EKF Diagnostics Presents Latest Diabetes Care Analyzers
- BioSystems Highlights New iFOB Integral System at MedLab 2019
- Beckman Coulter Exhibits New Hematology Analyzer in Middle East
- Agappe Diagnostics Displays Analyzers and Solutions at Middle East Congress
- Abbott Highlights Point of Care Management Solutions
Channels
Clinical Chemistry
view channel
International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
Interpreting serum calcium can be clinically challenging when albumin levels vary, especially in patients with chronic illness or kidney disease. For decades, laboratories have used formulas to adjust... Read more
Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
Prostate cancer is among the most common cancers in men, and the role of population screening has remained controversial because of overdiagnosis and overtreatment. Health systems have sought clearer,... Read moreMolecular Diagnostics
view channel
Microbial Saliva Test Could Help Triage Esophageal Cancer Risk
Esophageal squamous cell carcinoma (ESCC) is highly lethal, partly because many patients are diagnosed only after swallowing becomes difficult and treatment options are largely palliative.... Read more
Expanded DPYD Genotyping Test Supports Safer Chemotherapy Dosing
Fluoropyrimidines such as 5-fluorouracil (5-FU) are chemotherapy drugs prescribed to more than two million cancer patients each year, but 10–20% of patients can experience severe, and sometimes fatal,... Read more
Multi-Omics Profiling Helps Predict BCG Response and Recurrence in Bladder Cancer
High-risk non–muscle-invasive bladder cancer frequently recurs after therapy, with about 30% of patients relapsing and roughly 10% dying within two years despite tumor resection, surveillance, and Bacillus... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read more
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read moreMicrobiology
view channel
Study Finds Hidden Mpox Infections May Drive Ongoing Spread
Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read morePathology
view channel
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more
AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read moreTechnology
view channel
AI Tool Automates Validation of Laboratory Software Configuration Changes
Regulated laboratories face heavy documentation and requalification demands when software configurations change, slowing improvements and discouraging beneficial updates. A new capability now automates... Read more
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read moreIndustry
view channel
Strategic Collaboration Advances RNA Foundation Models for Precision Oncology
Bulk RNA sequencing is increasingly used to study tumor biology, but standard analyses often reduce results to gene-level summaries that miss important transcript variants and mutation patterns.... Read more





.jpg)



